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Abstract—In this study, the effects of some clinical variables on the survival times of patients with bladder cancer were examined. The 
effects of these variables on sub-distribution of the failure types were determined using the proportional sub-distribution hazards 
regression model described in Fine and Gray (1999). Published dataset on 294 bladder cancer patients with four clinical outcomes were 
analyzed using Cumulative Incidence Function approach. The four outcomes included 184 ( 64%) patients that experienced recurrence of 
bladder cancer after receiving chemotherapy treatments. Two patients died of bladder cancer while 27 patients died of other causes and the 
remaining 76 patients did not experienced any of these three outcomes, and as a result, were considered censored. Among the covariates 
considered, only the patients’ initial number of tumors and initial size of tumor were incorporated into our analysis due to high proportion 
of missing observations in others. Results from this work showed that, patients with tumour recurrence have highest risk of dying than 
those from other causes. Further results showed that, the number of tumor was positively associated with the recurrence of cancer of the 
bladder                     . However, the size of the tumor did not demonstrate a significant effect on the patients’ survival time. It 
can therefore, be concluded that patients with tumor recurrence have low probability of survival from bladder cancer than patients that 
experienced other events. Above all, number, but not size of tumor could adversely affect the survival time of bladder cancer patients, 
especially those with tumor recurrence after bladder cancer treatment. 
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1. INTRODUCTION 
he urinary bladder is a hollow, balloon-like organ 
located in the pelvis that collects and stores urine 
until it is ready to be excreted from the body and 
bladder cancer is the abnormal growth of tissue in the 
bladder. The literature has it that urinary bladder cancer 
is one of the most common cancers worldwide, with the 
highest incidence in industrialized countries (Zarzouret 
al., 2008). Bladder cancer is the fourth leading cause 
of cancer and the ninth leading cause of cancer deaths 
among American men with approximately 60,000 new 
cases diagnosed each year (MGBC, 2015). Bladder cancer 
incidence is lowest in Asia and South America, 
approximately 70% lower than what is being 
experienced in the western industrialized countries 
(Zarzour et al., 2008). 
 
Some of the identified risk factors of bladder cancer 
occurrence are smoking, occupational exposure, 
chemotherapeutic drugs, infections, gender, age, race 
and radiation therapy to the pelvic area (Jacob, 2015) 
among others. Cigarette smoking is known to be the 
greatest risk factor for bladder cancer with up to 65% 
and 25% of cases occurring in men and women 
respectively (Burch, 1989; Seripa et al., 2001). The above 
statistics simply showed that bladder cancer occurrence 
is gender sensitive with men mostly affected than the 
women. Individuals with occupational exposure to dyes, 
rubbers, textiles, paints, leathers, and certain chemicals 
(e.g. polycyclic aromatic hydrocarbons such as benzene 
and beta-naphthylamine) are at higher risk for 
developing bladder cancer (Seripa et al., 2001). Cases of 
bladder cancer are also common among the elderly 
population with about 50% of cases occurring in people 
aged 72 or older while the median age of diagnosis is 
around 65 years (MGBC, 2015). 
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The use of certain drugs for the treatment of cancer, 
particularly cyclophosphamide (Cytoxan), has equally 
been linked to the development of transitional cell 
carcinoma of the bladder (Jacob, 2015). Chronic or 
recurrent urinary tract infections, schistosomiasis, 
kidney stones, bladder stones, and long-term indwelling 
bladder catheters have all been linked to squamous cell 
carcinoma of the bladder (Seripa et al., 2001; Jacob, 2015). 
 
There are four primary types of bladder tumours that 
can be distinguished on the basis of the appearance 
(morphology) of the cells under a microscope. The first 
and the most common one is the Transitional cell 
carcinoma, which is also known as urothelial carcinoma 
(ACS, 2015). This type of bladder cancer affects the 
transitional epithelium that lines the wall of the bladder. 
More than 90% of bladder tumours are classified as 
transitional cell carcinomas (Seripa et al., 2001).The 
second one is the Squamous cell carcinoma which 
represents about 4% of all bladder tumours and is most 
commonly associated with chronic irritation of the 
bladder that can be caused by long-term indwelling 
bladder catheters or by bladder calculi (stones) (Jacob, 
2015). Another one is the adenocarcinoma which is an 
extremely rare form of bladder cancer accounting for less 
than 1% of all bladder tumours. The last one is the Small 
cell carcinoma which is also very rare and represents 
about 1% of all bladder tumours (Jacob, 2015). Generally, 
it is known that at the time of diagnosis, approximately 
75% of bladder tumours are superficial; 20% are 
invasive; and up to 5% are metastatic in nature (MGBC, 
2015). 
 
According to the World Health Organization (WHO), 
specific fruit and vegetables had been found to act as 
catalyst at reducing the risk of bladder cancer (Brinkman 
& Zeegers, 2008). Fruits and yellow-orange vegetables, 
particularly carrots and those containing selenium, are 
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probably associated with a moderately reduced risk of 
bladder cancer. Citrus fruits and cruciferous vegetables 
were also identified as having a possibly protective 
effect against the tumour (CCC, 2015). However, study 
by Brinkman & Zeegers (2006) showed little correlation 
between cancer reduction and high consumption of 
fruits and vegetables as compared to the statistically 
significant reduction among men that consumed large 
amounts of cruciferous vegetables. 
 
One of the objectives for treating patients with bladder 
cancer might be to remove the tumour or to prevent the 
tumour recurrence/metastasis or to prevent tumour 
progression from superficial to muscle-invasive bladder 
cancer. In any of these cases, the possible effects of some 
other prognostic factors other than that of the 
chemotherapy might be significantly important at 
predicting the survival times of the patients. This study 
therefore seeks to examine the effects of some of these 
factors as they affect the treatment of patients with 
bladder cancer tumours. 
2. MATERIALS AND METHODS 
2.1 Data Description 
The data used in this work were published data which 
had been previously discussed in the literature (see 
Andrews et al., 1985 and Wei et al., 1989). The data can 
be accessed in the R statistical software through the 
library ‘survival’.  
 
The data were on 294 bladder cancer patients with four 
clinical outcomes that represented the patients’ status or 
outcomes (events)at the end of the study. These 
outcomes included patients with local bladder cancer 
tumour recurrence after receiving chemotherapy 
treatment, patients that died of bladder cancer, patients 
that died of other causes different from bladder cancer 
and patients that did not experience any of the above 
three clinical outcomes, and as a result, were considered 
censored. 
 
Based on the four categories of clinical outcomes, all the 
294 bladder cancer patients in this study therefore 
included 189 (about 64%) patients that experienced 
recurrence of bladder cancer, 2 patients that died of 
bladder cancer disease and the 27 patients that died of 
other causes while remaining 76 patients were censored.  
Each patient in this study was administered with one of 
these chemotherapy treatments – Placebo, Pyridoxine 
(vitamin B6) and Thiotepa (an antineoplastic drug).Thus, 
of the entire 294 bladder cancer patients in the study, 128 
were administered with placebo, 85 with Pyridoxine and 
81 with Thiotepa over all the four clinical outcomes.  
 
About 68% (87), 67% (57) and 56% (45) of the patients 
that received Placebo, Pyridoxine and Thiotepa 
respectively had recurrence of bladder cancer tumour 
while one of the two patients that died of bladder cancer 
received placebo and the other one were administered 
with Thiotepa.  
 
Out of the 27 patients that died of other (unknown) 
causes different from bladder cancer, 10 (37%) patients 
were given Placebo, 7 (26%) patients received Pyridoxine 
and the remaining 10 (37%) received Thiotepa. Details of 
the patients’ characteristics in this study are provided in 
Table 1. In this clinical experiment, no patients 
experience more than one outcome (event). 
 
Table 1. Summary of the characteristics of 294 bladder cancer patients with respect to the number and types of 
events (outcomes) as well as the chemotherapy treatment received. 
 
Chemotherapy 
Treatment 
Events (Outcomes) 
Total 
Censored 
Cases of 
Tumour 
Recurrence 
Death from 
Bladder Cancer 
Disease 
Death due to 
unknown causes 
(Other Deaths) 
Placebo  30 87 1 10 128 
pyridoxine(vitamin B6) 21 57 0 7 85 
Thiotepa  25 45 1 10 81 
Total 76 189 2 27 294 
 
Among the metrical covariates in the data were the 
patients’ initial number of tumours and initial size of 
tumour. These two were incorporated in the analysis 
while others were ignored due to high proportion of 
missing observations in them. 
There are various ways of modelling competing risks 
data which include parametric and non-parametric 
techniques. In this work, the non-parametric approach of 
cumulative incidence function is adopted for modeling 
the data. All analyses were performed within the 
environment of R statistical package (www.r-
project.org).  
 
2.2 Model Specification 
Competing risks usually arises in studies in which there 
are more than two (   ) mutually exclusive events or 
outcome of interest into which an individual may be 
classified. In other words, there are   (   ) mutually 
exclusive causes of failure and an individual can only 
experience only one of the causes at the end of the study. 
When competing risks are present, classical survival 
analysis techniques (Dalgaard, 2002; Pintilie, 2006; Yahya 
& Ulm, 2009) may not be appropriate to be adopted for 
modeling such data. 
There are four events (outcomes) of interest in this study 
with   being defined as follows: 
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The empirical estimate of the cumulative incidence 
function (CIF) for cause   is given by (Fine, and Gray, 
1999; Aalen, 1978): 
 
       
                                         
 
                    (2) 
where   is the total number of observations. Thus, the 
CIF can be calculated as the sum, over all of the 
probabilities, of observing event   at time   while the 
individual is still at risk. That is to say that, the 
individual did not experience any event prior to   . If we 
define the probability of remaining event-free prior to    
as      , itthen follows that the joint probability of being 
event-free immediately prior to    and experiencing an 
event of type   at    can be computed by (Lin, 1997) 
                                     (3) 
where     is the cause-specific hazard for event   at time 
  . Intuitively,given that an individual has not 
experienced an event of any typeup to     , the 
probability of an event of type   in the interval      to 
  can be estimated as 
   
  
 where     is the number of 
event   at   . It then follows that 
        
   
  
                           (4) 
Thus, the CIF estimator for an event of type   depends 
not only on the number of individuals who have 
experienced this type of event, but also on the number of 
individuals who have not experienced any other type of 
event. The CIF represents the probability that an 
individual will experience an event of type  at time    
(Pintilie, 2006; Scrucca et al., 2007). 
 
2.2.1 Model-Based Estimation of the CIF 
The predicted CIF can be calculated for a certain value of 
the covariates using the equation 
                           (5) 
 
 
 
where     is the cumulative hazards of sub-distribution 
regression model which can be estimated using a 
Breslow-type estimator (Gray, 1988; Fine & Gray, 1999) 
of the form; 
              
          
                  
       (6) 
The outer sum is over all time points for which an event 
of interest was observed. 
3. RESULTS AND DISCUSSION  
Results from the CIF model fitted to the bladder cancer 
data are presented in this section. The Fig 1 represents 
the probability of observing these events at various time 
points (in months). The curve showed that, bladder 
cancer patients have highest risk of experiencing local 
tumour recurrence than experiencing deaths either from 
bladder cancer disease or from any other causes different 
from bladder cancer tumour. Further results indicated 
that, as the month of experiencing the disease increases 
the probability of observing the clinical outcome of 
interest increases. For example, the probabilities 
(converted to %) that a bladder cancer patient 
experiences local tumour recurrence by 10, 20, 30 and 40 
months after receiving chemotherapy treatments were 
52%, 63%, 68% and 72% respectively.  
 
A fairly detailed result is provided by Fig 2 where the 
estimated CIF were plotted separately for the three 
clinical outcomes (excluding the censored) based on the 
chemotherapy treatments received by the patients. 
 
It can be observed from the CIF graphs in Fig 2 that the 
incidence of local tumour recurrence in bladder cancer 
patients that had been previously treated for the disease 
is higher among those that received Pyridoxine 
treatments than those that were treated with Placebo or 
Thiotepa over the patients’ survival times. However, if 
consideration is on the risk of dying from bladder cancer 
alone, it can be found that the incidence of dying is 
higher among the patients that were treated with 
Thiotepa than those treated with other chemotherapies. 
Similarly, the incidence of death due to other disease is 
also higher among the patients that were treated with 
Thiotepa than those treated with some other 
chemotherapy treatments. 
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Fig. 1: Graph showing the plots of the estimated CIF on the bladder cancer patients over the three event types (patients’ clinical 
outcomes) excluding the censored observations against the patients’ survival times (in months). 
 
 
Fig. 2: Graph showing the separate plots of the estimated CIF on the bladder cancer patients over the three event types (patients’ 
clinical outcomes) excluding the censored observations based on the chemotherapy treatment received by the patients against the 
patients’ survival times (in months). 
 
Furthermore, the impacts of the two covariates (number 
of tumours and size of tumours) on local tumour 
recurrence in bladder cancer patients after they have 
been treated were determined. This was achieved by 
fitting the cumulative hazards of sub-distribution 
regression model on the data using equations (5) and (6). 
Results from the model were presented in Table 2.  
 
 
 
It can be observed from the results in Table 2 that that 
the number of tumours positively influenced the local 
tumour recurrence (RR = 1.1386, p = 0.0005) in bladder 
cancer patients with about 14% increase in relative risk 
of having local tumour recurrence. However, the size of 
tumour did not show any significant influence on 
patients’ local tumour recurrence over time (RR = 1.0280, 
p = 0.540). 
 
Table 2: Results of the cumulative hazards of sub-distribution regression model for testing the covariates effects on 
local tumour recurrence in bladder cancer patients. 
Covariates 
Coefficients 
( ) 
Relative Risk 
(RR) 
Standard Error 
( ) 
Statistic p-value 
Number of 
tumours 
0.1298 1.1386 0.0375 3.462 0.0005 
Size of tumours 0.0276 1.0280 0.0450 0.615 0.5400 
 
Without loss of generality, the impacts of number of 
tumours and size of tumours on other competing 
outcomes were suspended due to sparsity of 
observations as evident from the summary of patients’ 
characteristics provided in Table 1. 
 
 
 
The effects of number of tumours on the local tumour 
recurrence in bladder cancer patients was again made 
apparent by the plots of the CIF at some selected number 
of tumours as shown by the various graphs in Fig 3. 
Here, the estimated CIFs of patients that experienced 
local tumour recurrence but with 3, 4, 5 and 8 number of 
tumours with their corresponding tumour sizes 4, 3, 2 
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and 5 were plotted against their survival times. Results 
from various graphs in Fig 3 showed that the estimated 
CIF for local tumour recurrence in bladder cancer 
patients increases as the number of tumour in the 
patients increases over all the patients’ survival times. 
 
Fig 3: The graphs of the estimated CIFs for bladder cancer patients with local tumour recurrence with 3, 4, 5 and 8 number of 
tumours. 
4. CONCLUSION 
A non-parametric statistical method of analysis of 
survival data with more than one outcome (i.e. 
competing risks) was considered in this study. The 
cumulative incidence functions and sub-distribution 
hazard model has been employed to model the effects of 
some prognostic variables on the clinical outcomes of 
patients with bladder cancer tumours. Findings from 
this work indicated that bladder cancer patients have 
high probability of experiencing local recurrence after 
receiving chemotherapy treatments. Also, bladder cancer 
patients with local tumour recurrence have low 
probability of survival from bladder cancer than patients 
with other clinical outcomes. 
 
Above all, the number of tumours in bladder cancer 
patients influences the patients’ local tumour recurrence 
of bladder disease. However, the study affirmed the 
non-significant effect of the initial size of tumour in 
bladder cancer patients on their local tumour recurrence.  
It can therefore be concluded that, in the management of 
patients with bladder cancer tumours, the number, but 
not size of tumours could be a quick biomarker for local 
tumour recurrence in the patients. Finally, the summary 
statistics of the data, within the scope covered in this 
study, indicated that chemotherapy treatments of 
bladder cancer patients might later result into local 
tumour recurrence in the patients. Hence, more effective 
clinical methods for treating bladder cancer tumour 
might be desirable. 
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